Skip to content

Study · Observational study · 2014

4 results

Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw.

Kim KM, Park W, Oh SY, Kim HJ, Nam W, Lim SK, Rhee Y, Cha IH

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA20 Feb 2014Cited by 57 (Europe PMC)

PMID24554340 (opens in a new tab)DOI10.1007/s00198-014-2622-8 (opens in a new tab)PepBankPUB-24554340
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In refractory jaw osteonecrosis, 62.5% of teriparatide-treated subjects showed one stage of improvement.

    In plain wordsIn refractory jaw osteonecrosis, 62.5% of teriparatide-treated patients improved by one stage.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableOne-stage BRONJ improvement
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Subjects with one stage of BRONJ improvement
    62.5%
    teriparatide group

    Source sentences

    Summary
    In the TPTD group, 62.5% of the treated subjects showed one stage of improvement and the other 37.5% demonstrated a marked improvement, including two stages of improvement or complete healing, and there was not a single case that did not improve.
    2 context sentences
    Summary · context
    Twenty-four cases of intractable BRONJ were included: 15 subjects were assigned to the TPTD group and the other 9 subjects, who refused TPTD administration, were assigned to the non-TPTD group.
    Summary · context
    All subjects in both groups continued calcium and vitamin D supplementation and the TPTD group additionally received a daily subcutaneous injection of 20 μg TPTD for 6 months.
  2. 02HumanObservational studyEfficacy outcome

    In refractory jaw osteonecrosis, 37.5% of teriparatide-treated subjects improved by two stages or healed completely.

    In plain wordsIn refractory jaw osteonecrosis, 37.5% of teriparatide-treated patients improved markedly or healed completely.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableMarked BRONJ improvement
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Subjects with marked BRONJ improvement (two stages or complete healing)
    37.5%
    teriparatide group

    Source sentences

    Summary
    In the TPTD group, 62.5% of the treated subjects showed one stage of improvement and the other 37.5% demonstrated a marked improvement, including two stages of improvement or complete healing, and there was not a single case that did not improve.
    2 context sentences
    Summary · context
    Twenty-four cases of intractable BRONJ were included: 15 subjects were assigned to the TPTD group and the other 9 subjects, who refused TPTD administration, were assigned to the non-TPTD group.
    Summary · context
    All subjects in both groups continued calcium and vitamin D supplementation and the TPTD group additionally received a daily subcutaneous injection of 20 μg TPTD for 6 months.
  3. 03HumanObservational studyEfficacy outcome

    In refractory jaw osteonecrosis, teriparatide was linked to better clinical improvement than non-teriparatide care after 6 months.

    In plain wordsIn refractory jaw osteonecrosis, teriparatide was linked to better improvement than care without teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseClinical BRONJ improvement versus conservative care
    Study

    n: not reported in source

    Comparator
    Non-teriparatide conservative management
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The clinical improvement of BRONJ was statistically better in the TPTD group after the 6-month treatment (p < 0.05).
    2 context sentences
    Summary · context
    Twenty-four cases of intractable BRONJ were included: 15 subjects were assigned to the TPTD group and the other 9 subjects, who refused TPTD administration, were assigned to the non-TPTD group.
    Summary · context
    All subjects in both groups continued calcium and vitamin D supplementation and the TPTD group additionally received a daily subcutaneous injection of 20 μg TPTD for 6 months.

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 04HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther

    In teriparatide-treated jaw osteonecrosis, higher baseline serum vitamin D was linked to better clinical outcomes.

    In plain wordsIn teriparatide-treated jaw osteonecrosis, higher starting vitamin D was linked to better outcomes.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBaseline vitamin D and response
    Study

    n: not reported in source

    Comparator
    Lower baseline serum 25(OH)D
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Moreover, patients with higher baseline serum 25(OH)D levels showed better clinical therapeutic outcomes with TPTD.
    2 context sentences
    Summary · context
    Twenty-four cases of intractable BRONJ were included: 15 subjects were assigned to the TPTD group and the other 9 subjects, who refused TPTD administration, were assigned to the non-TPTD group.
    Summary · context
    All subjects in both groups continued calcium and vitamin D supplementation and the TPTD group additionally received a daily subcutaneous injection of 20 μg TPTD for 6 months.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.